Highlights Neurizon Therapeutics Limited

Equities

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 10:40:08 21/01/2026 am IST			5-day change	1st Jan Change
0.0820 ^AUD	-1.20%		0.00%	-3.53%

02/01	FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate	MT
02/01	Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001	RE

Highlights

20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT
02/01	FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate	MT
02/01	Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001	RE
29/12	Rights Issue: 2 new shares @ 0.08 AUD for 5 existing shares	FA
04/12	Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%	MT
26/11	Neurizon Therapeutics Limited Announces the Appointment of Justine Conway as Board Observer	CI
21/25/21	Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment	MT
06/25/06	Neurizon Therapeutics Limited Announces U.S. Food and Drug Administration Lifts Clinical Hold on Nuz-001	CI
06/25/06	FDA lifts clinical hold on Nuz-001	RE
06/25/06	Neurizon Therapeutics says US FDA lifts clinical hold on NUZ-001	RE
06/25/06	Neurizon Therapeutics Says US FDA Lifts Clinical Hold on Amyotrophic Lateral Sclerosis Drug Candidate	MT
26/25/26	Neurizon Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
26/25/26	Neurizon Therapeutics posts loss for year attributable a$16.6 million	RE
15/25/15	Neurizon Says US FDA Delays Decision on ALS Drug Application Clinical Hold; Shares Fall 6%	MT
25/25/25	Neurizon Therapeutics Submit Formal Response to US FDA for Investigational New Drug Application; Shares Up 19%	MT
10/25/10	Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial	MT
03/25/03	Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	MT
02/25/02	Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	MT
16/25/16	Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	CI
04/25/04	Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line	MT
04/25/04	Neurizon Therapeutics Limited Announces Results from an Additional Independent Study Carried Out in Partnership with the University of Queensland	CI
01/25/01	Neurizon Therapeutics Limited Announces Results from an Independent Study Conducted in Collaboration with Tessara Therapeutics	CI
24/25/24	Neurizon Therapeutics Limited Provides Update on Preparation for Entry into the Healey & AMG Center	CI
17/25/17	Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%	MT
17/25/17	Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Neurizon Therapeutics Limited

Equities

NUZ

AU0000357261

Pharmaceuticals

Highlights

Filters